Actinium Announces New Data From Ongoing Phase 1/2 Trial of Actimab-A Demonstrating Safety and Robust Clinical Efficacy in High Risk Elderly Acute Myeloid Leukemia Patients Strong Anti-Leukemic Effect Demonstrated in Cohort 3; No Dose Limiting Toxicities Observed
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.